DelveInsight’s, “Peanut Allergy Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Peanut Allergy pipeline landscape. It covers the Peanut Allergy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Peanut Allergy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Peanut Allergy Treatment Landscape. Click here to read more @ Peanut Allergy Pipeline Outlook
Key Takeaways from the Peanut Allergy Pipeline Report
- In August 2025, DBV Technologies announced a Phase 3 randomized double-blind, placebo-controlled (DBPC) study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).
- DelveInsight’s Peanut Allergy Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Peanut Allergy treatment.
- The leading Peanut Allergy Companies such as DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
- Promising Peanut Allergy Pipeline Therapies such as Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
Discover groundbreaking developments in Peanut Allergy therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Peanut Allergy Clinical Trials Assessment
Peanut Allergy Emerging Drugs Profile
- DBV712: DBV Technologies
DBV712 is an investigational epicutaneous immunotherapy (EPIT) product developed by DBV Technologies for the treatment of peanut allergy. It consists of a patch that delivers microgram amounts of peanut protein through the skin, aiming to desensitize the immune system over time and reduce allergic reactions upon accidental exposure. DBV712 is designed for daily application on the back, leveraging the skin’s immune properties to induce tolerance with a favorable safety profile. This non-invasive approach offers a convenient alternative to oral immunotherapy, particularly for pediatric patients. Currently, the drug is in Phase III stage of its development for the treatment of Peanut Allergy.
- PVX-108: Aravax Pty Ltd
PVX108 comprises a mixture of peptides that represent sequences from peanut allergens which are critical for recognition by peanut-specific T cells. Unlike other peanut allergy immunotherapies, PVX108 does not contain the peanut proteins (allergens) which cause severe allergic reactions. PVX108 is being developed as a safe and simple therapy to restore and maintain tolerance, and reduce the risk of severe allergic reactions upon accidental exposure to peanuts. PVX108 therefore offers several advantages over other approaches. It has negligible risk of activating basophils and mast cells in people with peanut allergy. It does not require careful dose escalation or daily administration. It retrains the immune system to restore and maintain tolerance, reducing the risk of anaphylaxis. PVX108 does not contain natural extracts or whole allergens and has been engineered to be incapable of triggering acute allergic reactions. It has been designed to provide a safe, convenient and long-lasting treatment with monthly dosing through essentially needle-free intradermal administration. Currently, the drug is in Phase II stage of its development for the treatment of Peanut Allergy.
- INP20: InnoUp Farma S.L.
INP20 is an innovative oral vaccine developed by InnoUp Farma for the treatment of peanut allergy. Utilizing proprietary nanoparticle technology, INP20 encapsulates whole peanut extract to deliver controlled release directly in the gut, minimizing systemic absorption and reducing the risk of severe allergic reactions. The formulation is designed to mask allergens from immune detection while simultaneously promoting immunomodulation by targeting antigen-presenting cells. This dual mechanism offers a promising approach to induce long-term tolerance in peanut-allergic individuals, with a clean safety profile and simplified dosing. Currently, the drug is in Phase I/II stage of its development for the treatment of Peanut Allergy.
The Peanut Allergy Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Peanut Allergy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Peanut Allergy Treatment.
- Peanut Allergy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Peanut Allergy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Peanut Allergy market
Stay informed about the Peanut Allergy pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Peanut Allergy Unmet Needs
Peanut Allergy Companies
DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
Peanut Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Peanut Allergy Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Transform your understanding of the Peanut Allergy Pipeline! See the latest progress in drug development and clinical research @ Peanut Allergy Market Drivers and Barriers, and Future Perspectives
Scope of the Peanut Allergy Pipeline Report
- Coverage- Global
- Peanut Allergy Companies- DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, and others.
- Peanut Allergy Pipeline Therapies- Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others.
- Peanut Allergy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Peanut Allergy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Immunological and Autoimmune Disorders Research–Access the Full Peanut Allergy Pipeline Analysis Today! @ Peanut Allergy Drugs and Companies
Table of Contents
- Introduction
- Executive Summary
- Peanut Allergy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Peanut Allergy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- DBV712: DBV Technologies
- Mid Stage Products (Phase II)
- PVX-108: Aravax Pty Ltd
- Early Stage Products (Phase I/II)
- INP20: InnoUp Farma S.L.
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- Peanut Allergy Key Companies
- Peanut Allergy Key Products
- Peanut Allergy- Unmet Needs
- Peanut Allergy- Market Drivers and Barriers
- Peanut Allergy- Future Perspectives and Conclusion
- Peanut Allergy Analyst Views
- Peanut Allergy Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight